BUILDER'S SANDBOX
Build This Paper
Use an AI coding agent to implement this research.
OpenAI CodexAI Agent
Lightweight coding agent in your terminal.
Claude CodeAI Agent
Agentic coding tool for terminal workflows.
AntiGravity IDEScaffolding
AI agent mindset installer and workflow scaffolder.
CursorIDE
AI-first code editor built on VS Code.
VS CodeIDE
Free, open-source editor by Microsoft.
Startup Essentials
MVP Investment
$9K - $13K
6-10 weeksEngineering
$8,000GPU Compute
$800SaaS Stack
$300Domain & Legal
$1006mo ROI
0.5-1x
3yr ROI
6-15x
GPU-heavy products have higher costs but premium pricing. Expect break-even by 12mo, then 40%+ margins at scale.
Talent Scout
J
Jiayang Wu
Westlake University
J
Jiale Zhou
Westlake University
R
Rubo Wang
Chinese Academy of Sciences
X
Xingyi Zhang
Mohamed bin Zayed University of Artificial Intelligence
Find Similar Experts
Biotech experts on LinkedIn & GitHub
References
References not yet indexed.
Founder's Pitch
"MERA leverages retrieval-augmented, multimodal mixture-of-experts for state-of-the-art protein active site identification, enhancing drug discovery efforts."
Commercial Viability Breakdown
0-10 scaleHigh Potential
2/4 signals
Quick Build
4/4 signals
Series A Potential
4/4 signals
Sources used for this analysis
arXiv Paper
Full-text PDF analysis of the research paper
GitHub Repository
Code availability, stars, and contributor activity
Citation Network
Semantic Scholar citations and co-citation patterns
Community Predictions
Crowd-sourced unicorn probability assessments
Analysis model: GPT-4o · Last scored: 3/2/2026
🔭 Research Neighborhood
Generating constellation...
~3-8 seconds
Why It Matters
Identifying protein active sites accurately is crucial for drug discovery and understanding protein functions. Advances in this area can lead to breakthroughs in the development of new therapeutics by targeting specific proteins more effectively.
Product Angle
This technology could be packaged as a cloud-based API service that integrates into biotech and pharmaceutical research pipelines, offering tools for precision drug targeting and discovery research.
Disruption
MERA could potentially replace traditional computational methods that rely heavily on single-modality data. Its improved accuracy and reliability from multimodal integration could become a preferred method in protein analysis.
Product Opportunity
The burgeoning protein drug discovery market, which is driven by the need for more precise targeting of protein functions in diseases, offers substantial opportunity. Pharmaceutical companies and research institutions could be major clients.
Use Case Idea
An API providing on-demand protein active site identification for pharmaceutical companies looking to streamline their drug discovery processes by rapidly assessing potential target proteins.
Science
MERA is a framework that enhances protein active site identification by using a mixture of experts approach augmented with retrieval mechanisms. The system dynamically retrieves contextual information from various perspectives (chain, sequence, active-site) and uses Dempster-Shafer theory for trustworthiness in multimodal fusion, improving reliability and prediction accuracy.
Method & Eval
Tested on ProTAD-Gen and TS125 datasets, MERA demonstrated state-of-the-art performance with a 90% AUPRC on active site prediction, outperforming existing solutions in identifying peptide-binding sites as well.
Caveats
The method relies on the availability and quality of external datasets and embeddings. Its effectiveness could diminish without reliable access to these resources. Additionally, deploying it at scale could require substantial computational resources.
Author Intelligence
Jiayang Wu
Westlake University
Jiale Zhou
Westlake University
Rubo Wang
Chinese Academy of Sciences
Xingyi Zhang
Mohamed bin Zayed University of Artificial Intelligence
Xun Lin
Westlake University
Tianxu Lv
Jiangnan University
Leong Hou U
University of Macau
Yefeng Zheng
Westlake University